Novo Nordisk Shares Are Trading Higher After the Company Entered Into an Expanded Agreement With Valo Health to Discover and Develop Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease.
Novo Nordisk Shares Are Trading Higher After the Company Entered Into an Expanded Agreement With Valo Health to Discover and Develop Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease.
諾和諾德的股票在與Valo Health達成擴大協議後交易上漲,該協議旨在發現和開發肥胖症、2型糖尿病和心血管疾病的治療方案。
Novo Nordisk Shares Are Trading Higher After the Company Entered Into an Expanded Agreement With Valo Health to Discover and Develop Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease.
諾和諾德的股票在與Valo Health達成擴大協議後交易上漲,該協議旨在發現和開發肥胖症、2型糖尿病和心血管疾病的治療方案。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。